These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38574400)

  • 41. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.
    Weaver NA; Doeven T; Barkhof F; Biesbroek JM; Groeneveld ON; Kuijf HJ; Prins ND; Scheltens P; Teunissen CE; van der Flier WM; Biessels GJ;
    Neurobiol Aging; 2019 Dec; 84():225-234. PubMed ID: 31500909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contributions of amyloid beta and cerebral small vessel disease in clinical decline.
    Moonen JEF; Haan R; Bos I; Teunissen C; van de Giessen E; Tomassen J; den Braber A; van der Landen SM; de Geus EJC; Legdeur N; van Harten AC; Trieu C; de Boer C; Kroeze L; Barkhof F; Visser PJ; van der Flier WM
    Alzheimers Dement; 2024 Mar; 20(3):1868-1880. PubMed ID: 38146222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thickness.
    Tan CH; Chew J; Zhang L; Gulyás B; Chen C;
    Neurobiol Aging; 2022 Jul; 115():12-19. PubMed ID: 35453034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. White matter hyperintensities: relationship to amyloid and tau burden.
    Graff-Radford J; Arenaza-Urquijo EM; Knopman DS; Schwarz CG; Brown RD; Rabinstein AA; Gunter JL; Senjem ML; Przybelski SA; Lesnick T; Ward C; Mielke MM; Lowe VJ; Petersen RC; Kremers WK; Kantarci K; Jack CR; Vemuri P
    Brain; 2019 Aug; 142(8):2483-2491. PubMed ID: 31199475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determinants and Temporal Dynamics of Cerebral Small Vessel Disease: 14-Year Follow-Up.
    Cai M; Jacob MA; van Loenen MR; Bergkamp M; Marques J; Norris DG; Duering M; Tuladhar AM; de Leeuw FE
    Stroke; 2022 Sep; 53(9):2789-2798. PubMed ID: 35506383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
    Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
    Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence.
    Brickman AM; Zahodne LB; Guzman VA; Narkhede A; Meier IB; Griffith EY; Provenzano FA; Schupf N; Manly JJ; Stern Y; Luchsinger JA; Mayeux R
    Neurobiol Aging; 2015 Jan; 36(1):27-32. PubMed ID: 25155654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants.
    Hong H; Hong L; Luo X; Zeng Q; Li K; Wang S; Jiaerken Y; Zhang R; Yu X; Zhang Y; Lei C; Liu Z; Chen Y; Huang P; Zhang M;
    Alzheimers Res Ther; 2024 Feb; 16(1):43. PubMed ID: 38378607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy.
    Fiford CM; Manning EN; Bartlett JW; Cash DM; Malone IB; Ridgway GR; Lehmann M; Leung KK; Sudre CH; Ourselin S; Biessels GJ; Carmichael OT; Fox NC; Cardoso MJ; Barnes J;
    Hippocampus; 2017 Mar; 27(3):249-262. PubMed ID: 27933676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
    Shirzadi Z; Schultz SA; Yau WW; Joseph-Mathurin N; Fitzpatrick CD; Levin R; Kantarci K; Preboske GM; Jack CR; Farlow MR; Hassenstab J; Jucker M; Morris JC; Xiong C; Karch CM; Levey AI; Gordon BA; Schofield PR; Salloway SP; Perrin RJ; McDade E; Levin J; Cruchaga C; Allegri RF; Fox NC; Goate A; Day GS; Koeppe R; Chui HC; Berman S; Mori H; Sanchez-Valle R; Lee JH; Rosa-Neto P; Ruthirakuhan M; Wu CY; Swardfager W; Benzinger TLS; Sohrabi HR; Martins RN; Bateman RJ; Johnson KA; Sperling RA; Greenberg SM; Schultz AP; Chhatwal JP;
    JAMA Neurol; 2023 Dec; 80(12):1353-1363. PubMed ID: 37843849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are the brain's vascular and Alzheimer pathologies additive or interactive?
    Koncz R; Sachdev PS
    Curr Opin Psychiatry; 2018 Mar; 31(2):147-152. PubMed ID: 29232251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
    Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
    Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
    Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
    JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identifying preclinical vascular dementia in symptomatic small vessel disease using MRI.
    Lambert C; Zeestraten E; Williams O; Benjamin P; Lawrence AJ; Morris RG; Mackinnon AD; Barrick TR; Markus HS
    Neuroimage Clin; 2018; 19():925-938. PubMed ID: 30003030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Regional White Matter Hyperintensities With Longitudinal Alzheimer-Like Pattern of Neurodegeneration in Older Adults.
    Rizvi B; Lao PJ; Chesebro AG; Dworkin JD; Amarante E; Beato JM; Gutierrez J; Zahodne LB; Schupf N; Manly JJ; Mayeux R; Brickman AM
    JAMA Netw Open; 2021 Oct; 4(10):e2125166. PubMed ID: 34609497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory.
    Han JW; Maillard P; Harvey D; Fletcher E; Martinez O; Johnson DK; Olichney JM; Farias ST; Villeneuve S; Jagust W; Mungas D; DeCarli C
    Neurology; 2020 Nov; 95(19):e2622-e2634. PubMed ID: 32732300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.